TGFB1 and breast carcinoma: These results were reproduced in the breast cancer cell lines MCF7 and A459 (6) and in addition it was shown that inhibition of ADAM17 by a metalloprotease inhibitor—BB94—led to the upregulation of TGF-β signaling.